Abstract: Non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor are disclosed. The compounds have the general formula (I) in which R is hydrogen or methyl; W is a single bond or an oxygen atom; n=3; X is hydrogen or a —NR1R2 amino group in which R1 and R2 can be independently hydrogen or a group which is methyl, ethyl, n-propyl, or isopropyl; Y is a —NR3R4R5 quaternary ammonium group in which R3, R4, R5 can be independently a group which is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or n-pentyl; and the enantiomers and enantiomeric mixtures thereof. Pharmaceutical compositions containing these compounds and methods of using the compounds to treat patients having conditions, disorders or diseases involving activation of bradykinin B2 receptors are also disclosed.

Abstract: Non-peptide compounds of formula (I) having activity as specific antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an alpha, alpha-disubstituted amino acid at least one amino group, free or salified, or the corresponding ammonium quaternary salt. These BK receptor antagonists are a novel class of medicaments which can be used in all the disorders in which the receptors are involved.

Abstract: Compounds of structure (I) having histone deacetylase (HDAC) inhibitor activity are described. The compounds are chemically characterised by the presence of hydroxamic acid, with zinc as chelator, and an aromatic nucleus connected by a linker in which either a bicyclic aromatic system or a piperidino ring are present.

Abstract: Disclosed are non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an amino acid alpha substituted with a cyclic group and by a tetraalkylammonium group. Also disclosed are pharmaceutical compositions containing the compound, and methods of using the compounds to treat patients having conditions, disorders or diseases involving activation of bradykinin B2 receptor.

Abstract: The present invention describes compounds with formula (I) having linear structure basic properties useful as NK-2 antagonists; pharmaceutical compositions containing said compounds are also described and processes for their preparation.

Abstract: Non-peptide compounds of formula (I) having activity as specific antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an alpha, alpha-disubstituted amino acid at least one amino group, free or salified, or the corresponding ammonium quaternary salt.

Abstract: The present invention relates to Distamycin compounds of formula (I), methods of use and their pharmaceutical compositions.

Abstract: Triazinylphosphonic acids of general formula (I): ##STR1## obtained by subsequent condensation reaction of a cyanuric halide with a osphite and with amines, and then by hydrolysis reaction of the intermediate thus obtained. The compounds of general formula (I) are used in particular as flame retardant additives.

Abstract: Triazinylphosphonic acids of general formula (I): ##STR1## obtained by subsequent condensation reaction of a cyanuric halide with a osphite and with amines, and then by hydrolysis reaction of the intermediate thus obtained; The compounds of general formula (I) are used in particular as flame retardant additives.

Abstract: Self-extinguishing polymeric compositions endowed with high self-extinguishing characteristics when exposed to a flame, based on thermoplastic polymers endowed with elastomeric properties, in particular olefinic polymers or copolymers, comprising:(a) from 90 to 40 parts by weight of a thermoplastic polymer, or a polymer with elastomeric properties;(b) from 10 to 60 parts by weight of one or more derivatives of 2,4-diamino-1,3,5-triazinyl-6-phosphonic acid having the general formula (I): ##STR1##

Abstract: Derivatives of triazinylphosphonic acid having the general formula (I): ##STR1## obtained by means of the reaction of condensation of a cyanuric halide w an ester of phosphorous acid and subsequent reaction of substitution with a polyamine and an amine.